Farallon Capital Management’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-3,150,857
| Closed | -$105M | – | 186 |
|
|
2024
Q3 | $105M | Buy |
3,150,857
+210,357
| +7% | +$7.24M | 0.46% | 52 |
|
|
2024
Q2 | $79.5M | Hold |
2,940,500
| – | – | 0.34% | 51 |
|
|
2024
Q1 | $63.5M | Buy |
2,940,500
+1,380,000
| +88% | +$30.1M | 0.27% | 55 |
|
|
2023
Q4 | $9.41M | Hold |
1,560,500
| – | – | 0.04% | 83 |
|
|
2023
Q3 | $8.68M | Buy |
1,560,500
+560,500
| +56% | +$3.61M | 0.04% | 92 |
|
|
2023
Q2 | $7.34M | Sell |
1,000,000
-560,500
| -36% | -$4.24M | 0.04% | 96 |
|
|
2023
Q1 | $5.29M | Buy |
1,560,500
+750,000
| +93% | +$3.66M | 0.03% | 121 |
|
|
2022
Q4 | $2.64M | Hold |
810,500
| – | – | 0.02% | 164 |
|
|
2022
Q3 | $3.02M | Hold |
810,500
| – | – | 0.02% | 199 |
|
|
2022
Q2 | $2.5M | Hold |
810,500
| – | – | 0.01% | 202 |
|
|
2022
Q1 | $4.33M | Hold |
810,500
| – | – | 0.02% | 194 |
|
|
2021
Q4 | $3.92M | Hold |
810,500
| – | – | 0.02% | 195 |
|
|
2021
Q3 | $7.17M | Hold |
810,500
| – | – | 0.03% | 167 |
|
|
2021
Q2 | $7.39M | Hold |
810,500
| – | – | 0.03% | 158 |
|
|
2021
Q1 | $13.3M | Buy |
+810,500
| New | +$13.2M | 0.07% | 122 |
|
Farallon Capital Management's LBPH Position: Q4 2024 in Review
Farallon Capital Management sold out of Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q4 2024, closing a stake of 3,150,857 shares — an estimated $105M sold.
Farallon Capital Management first reported a position in LBPH in Q1 2021 and held it in 15 quarters. The position peaked at $105M in Q3 2024. 0 funds tracked by Wall St. Rank hold LBPH as of Q4 2024.
- Farallon Capital Management reported no remaining Longboard Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Farallon Capital Management sold 3,150,857 Longboard Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $105M.
- Farallon Capital Management first reported a position in Longboard Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 15 quarters.
- Farallon Capital Management's Longboard Pharmaceuticals, Inc. Common Stock position peaked at $105M in Q3 2024.
- 0 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q4 2024.
Based on Farallon Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.